Free Trial
NASDAQ:PLUR

Pluri Q3 2025 Earnings Results & Report

Pluri logo
$0.93 -0.01 (-1.06%)
Closing price 10/14/2026 03:54 PM Eastern
Extended Trading
$0.94 +0.01 (+1.18%)
As of 08:55 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pluri reported Q3 2025 earnings on May 13, 2025. The company reported EPS of -$0.94, while revenue was $0.43 million.

Earnings Announcement Details

Quarter
Q3 2025
Report Date
Time
After Market Closes

Pluri EPS Results

Actual EPS
-$0.94
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 4 quarters

Pluri Revenue Results

Actual Revenue
$0.43 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Pluri's next earnings date is estimated for Thursday, November 5, 2026, based on past reporting schedules.

Conference Call Resources

Pluri Q3 2025 Earnings FAQ

Pluri (NASDAQ:PLUR) reported earnings of -$0.94 per share for Q3 2025. The report was announced on Tuesday, May 13, 2025.

Pluri reported revenue of $0.43 million for Q3 2025.

Pluri's next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for Pluri on the company's earnings history page.

Pluri Earnings Headlines

Pluri (NASDAQ:PLUR) Shares Climb 5.1% - Here's Why
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
Pluri prices $3.3 million offering
See More Pluri Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Pluri? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pluri and other key companies, straight to your email.

About Pluri

Pluri (NASDAQ:PLUR) (NASDAQ: PLUR), formerly known as Pluristem Therapeutics, is a biotechnology company developing cell-based products using its proprietary three-dimensional cell expansion platform. The company’s technology is designed to produce large quantities of allogeneic cells, which are cells intended for use in patients other than the original donor, without requiring a tissue match.

Pluri’s research has focused primarily on placenta-derived stromal cells, marketed under the PLX platform. Its development programs have explored potential applications in regenerative medicine, including conditions involving tissue damage, inflammation, blood disorders and immune-related diseases. The company has also investigated cell-based solutions for areas beyond traditional therapeutics, including food technology and agricultural applications.

Founded as Pluristem Therapeutics, the company changed its name to Pluri as it broadened its focus beyond drug development. Pluri is based in Haifa, Israel, and its activities have included research collaborations and development efforts aimed at serving international healthcare and biotechnology markets. Yaky Yanay has served as the company’s chief executive officer.

View Pluri Profile